Modeling of US human papillomavirus (HPV) seroprevalence by age and sexual behavior indicates an increasing trend of HPV infection following the sexual revolution

Journal of Infectious Diseases

Volumn 216, Issue 5, 2017, Pages 604-611

  Ryser, Marc D ^a,b   Rositch, Anne ^c   Gravitt, Patti E ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cancer; Cohort effect; Human papillomavirus; Sexual revolution

Indexed keywords

ADULT; ANTIBODY DETECTION; ANUS CANCER; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; EXPOSURE; FEMALE; GROUPS BY AGE; HUMAN; MATHEMATICAL MODEL; MIDDLE AGED; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SELF REPORT; SEROPREVALENCE; SEXUAL BEHAVIOR; TREND STUDY; UNITED STATES; UTERINE CERVIX ADENOCARCINOMA; ADOLESCENT; INCIDENCE; ISOLATION AND PURIFICATION; NUTRITION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTOR; SEROEPIDEMIOLOGY; SEXUALITY; THEORETICAL MODEL; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MODELS, THEORETICAL; NUTRITION SURVEYS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; SEXUAL PARTNERS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 85030620295     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix333     Document Type: Article

References (21)

1. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31(SUPPL. 8):I1-31.
2. Yang DX, Soulos PR, Davis B, Gross CP, Yu JB. Impact of widespread cervical cancer screening: number of cancers prevented and changes in race-specific incidence. Am J Clin Oncol 2016. doi:10.1097/COC.0000000000000264.
3. Wang SS, Sherman ME, Hildesheim A, Lacey J V, Jr., Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100:1035-44.
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301.
5. Joseph DA, Miller J W, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113:2892-900.
6. Liu G, Hariri S, Bradley H, Gottlieb SL, Leichliter JS, Markowitz LE. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis 2015; 42:20-6.
7. Twenge JM, Sherman RA, Wells BE. Changes in American adults' sexual behavior and attitudes, 1972-2012. Arch Sex Behav 2015; 44:2273-85.
8. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-9.
9. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693-703.
10. Gargano JW, Unger ER, Liu G, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis 2017; 215:1070-79.
11. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9:423-30.
12. Liu G, Markowitz LE, Hariri S, Panicker G, Unger ER. Seroprevalence of 9 human papillomavirus types in the United States, 2005-2006. J Infect Dis 2016; 213:191-8.
13. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009; 200:1059-67.
14. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46:1647-55.
15. Desai S, Chapman R, Jit M, et al. Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis 2011; 38:622-9.
16. af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998; 177:1710-4.
17. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24(suppl 3):S3/178-86.
18. Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine 2014; 32:3237-42.
19. Laprise JF, Markowitz LE, Chesson H W, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis 2016; 214:685-8.
20. Lin SW, Ghosh A, Porras C, et al. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One. 2013; 8(1):e53067.
21. Bogaards JA, Xiridou M, Coupé VM, Meijer CJ, Wallinga J, Berkhof J. Model-based estimation of viral transmissibility and infection-induced resistance from the age-dependent prevalence of infection for 14 high-risk types of human papillomavirus. Am J Epidemiol 2010; 171:817-25.